Acetylation of the cell-fate factor dachshund determines p53 binding and signaling modules in breast cancer

Oncotarget

Volumn 4, Issue 6, 2013, Pages 923-935

  Chen, Ke ^a   Wu, Kongming ^a   Gormley, Michael ^a   Ertel, Adam ^a   Wang, Jing ^a   Zhang, Wei ^a   Zhou, Jie ^a   DiSante, Gabriele ^a   Li, Zhiping ^a   Rui, Hallgeir ^a   Quong, Andrew A ^a   McMahon, Steven B ^a,b   Deng, Haiteng ^c   Lisanti, Michael P ^b   Wang, Chenguang ^a,b   Pestell, Richard G ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Breast cancer; Cell fate; Dach; P53; Stem cells

Indexed keywords

DACH1 PROTEIN; EPIDERMAL GROWTH FACTOR; NICOTINAMIDE ADENINE DINUCLEOTIDE; PROTEIN P21; PROTEIN P53; RAD51 PROTEIN; SERINE; UNCLASSIFIED DRUG;

ACETYLATION; AMINO TERMINAL SEQUENCE; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL CYCLE ARREST; CELL FATE; CELL GROWTH; DROSOPHILA; HUMAN; MISSENSE MUTATION; NONHUMAN; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION;

ACETYLATION; AMINO ACID SEQUENCE; APOPTOSIS; BINDING SITES; BREAST NEOPLASMS; CELL CYCLE CHECKPOINTS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CHROMATIN; DNA DAMAGE; EYE PROTEINS; FEMALE; GENE EXPRESSION; HEK293 CELLS; HUMANS; MUTATION; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; SEQUENCE HOMOLOGY, AMINO ACID; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84880830761     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1094     Document Type: Article

References (41)

1. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, Olivier M. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat. 2007; 28(6):622-629.
2. Olivier M, Langerød A, Carrieri P, Bergh J, Klaar S, Eyfjord J, Theillet C, Rodriguez C, Lidereau R, Bièche I, Varley J, Bignon Y, Uhrhammer N, Winqvist R, Jukkola-Vuorinen A, Niederacher D, Kato S, Ishioka C, Hainaut P, Børresen-Dale AL. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res. 2006; 12(4):1157-1167.
3. Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol. 2007; 8(4):275-283.
4. Zhou J, Wang C, Wang Z, Dampier W, Wu K, Casimiro MC, Chepelev I, Popov VM, Quong A, Tozeren A, Zhao K, Lisanti MP, Pestell RG. Attenuation of Forkhead signaling by the retinal determination factor DACH1. Proc Natl Acad Sci U S A. 2010; 107(15):6864-6869.
5. Popov VM, Zhou J, Shirley LA, Quong J, Yeow WS, Wright JA, Wu K, Rui H, Vadlamudi RK, Jiang J, Kumar R, Wang C, Pestell RG. The cell fate determination factor DACH1 is expressed in estrogen receptor-alpha-positive breast cancer and represses estrogen receptor-alpha signaling. Cancer Res. 2009; 69(14):5752-5760.
6. Wu K, Katiyar S, Witkiewicz A, Li A, McCue P, Song LN, Tian L, Jin M, Pestell RG. The cell fate determination factor dachshund inhibits androgen receptor signaling and prostate cancer cellular growth. Cancer Res. 2009; 69(8):3347-3355.
7. Wu K, Li A, Rao M, Liu M, Dailey V, Yang Y, Di Vizio D, Wang C, Lisanti MP, Sauter G, Russell RG, Cvekl A, Pestell RG. DACH1 is a cell fate determination factor that inhibits cyclin D1 and breast tumor growth. Mol Cell Biol. 2006; 26(19):7116-7129.
8. Nan F, Lü Q, Zhou J, Cheng L, Popov VM, Wei S, Kong B, Pestell RG, Lisanti MP, Jiang J, Wang C. Altered expression of DACH1 and cyclin D1 in endometrial cancer. Cancer Biol Ther. 2009; 8(16):1534-1539.
9. Wu K, Jiao X, Li Z, Katiyar S, Casimiro MC, Yang W, Zhang Q, Willmarth NE, Chepelev I, Crosariol M, Wei Z, Hu J, Zhao K, Pestell RG. et al. Cell fate determination factor Dachshund reprograms breast cancer stem cell function. J Biol Chem. 2011; 286(3):2132-2142.
10. Adorno M, Cordenonsi M, Montagner M, Dupont S, Wong C, Hann B, Solari A, Bobisse S, Rondina MB, Guzzardo V, Parenti AR, Rosato A, Bicciato S, Balmain A, Piccolo S. A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell. 2009; 137(1):87-98.
11. Tang Y, Zhao W, Chen Y, Zhao Y, Gu W. Acetylation is indispensable for p53 activation. Cell. 2008; 133(4):612-626.
12. Feng L, Lin T, Uranishi H, Gu W, Xu Y. Functional analysis of the roles of posttranslational modifications at the p53 C terminus in regulating p53 stability and activity. Mol Cell Biol.2005; 25(13):5389-5395.
13. Krummel KA, Lee CJ, Toledo F, & Wahl GM.The C-terminal lysines fine-tune P53 stress responses in a mouse model but are not required for stability control or transactivation. Proc Natl Acad Sci USA.2005; 102(29):10188-10193.
14. Sykes SM, Mellert HS, Holbert MA, Li K, Marmorstein R, Lane WS, McMahon SB.Acetylation of the p53 DNAbinding domain regulates apoptosis induction. Mol Cell. 2006; 24(6):841-851.
15. Charvet C, Wissler M, Brauns-Schubert P, Wang SJ, Tang Y, Sigloch FC, Mellert H, Brandenburg M, Lindner SE, Breit B, Green DR, McMahon SB, Borner C, Gu W, Maurer U. Phosphorylation of Tip60 by GSK-3 determines the induction of PUMA and apoptosis by p53. Molecular cell. 2011; 42(5):584-596.
16. Tang Y, Luo J, Zhang W, Gu W. Tip60-dependent acetylation of p53 modulates the decision between cellcycle arrest and apoptosis. Mol Cell. 2006; 24(6):827-839.
17. Wu K, Yang Y, Wang C, Davoli MA, D'Amico M, Li A, Cveklova K, Kozmik Z, Lisanti MP, Russell RG, Cvekl A, Pestell RG.DACH1 inhibits transforming growth factorbeta signaling through binding Smad4. J Biol Chem. 2003; 278(51):51673-51684.
18. Nikulenkov F, Spinnler C, Li H, Tonelli C, Shi Y, Turunen M, Kivioja T, Ignatiev I, Kel A, Taipale J, Selivanova G. Insights into p53 transcriptional function via genome-wide chromatin occupancy and gene expression analysis. Cell Death Differ. 2012; 19(12):1992-2002.
19. Pietsch EC, Humbey O, & Murphy ME. Polymorphisms in the p53 pathway. Oncogene. 2006; 25(11):1602-1611.
20. Ikeda K, Watanabe Y, Ohto H, & Kawakami K. Molecular interaction and synergistic activation of a promoter by Six, Eya, and Dach proteins mediated through CREB binding protein. Mol Cell Biol. 2002; 22(19):6759-6766.
21. Dumont P, Leu JI, Della Pietra AC, 3rd, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet. 2003; 33(3):357-365.
22. Olivier M, Hollstein M, & Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol.2010; 2(1):a001008.
23. Bonafe M, Salvioli S, Barbi C, Mishto M, Trapassi C, Gemelli C, Storci G, Olivieri F, Monti D, Franceschi C. p53 codon 72 genotype affects apoptosis by cytosine arabinoside in blood leukocytes. Biochem Biophys Res Commun. 2002; 299(4):539-541.
24. Joerger AC, Fersht AR. Structure-function-rescue: the diverse nature of common p53 cancer mutants. Oncogene. 2007; 26(15):2226-2242.
25. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, Crowley D, Jacks T. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell. 2004; 119(6):847-860.
26. Vousden KH, Prives C. Blinded by the Light: The Growing Complexity of p53. Cell. 2009; 137(3):413-431.
27. Feng Z, Levine AJ.The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein. Trends Cell Biol. 2010; 20(7):427-434.
28. Meyers FJ, Chi SG, Fishman JR, deVere White RW, Gumerlock PH. p53 mutations in benign prostatic hyperplasia. Journal of the National Cancer Institute. 1993; 85(22):1856-1858.
29. Gu W, Roeder RG. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell.1997; 90(4):595-606.
30. Berger SL. Keeping p53 in check: a high-stakes balancing act. Cell. 2010; 142(1):17-19.
31. Smith J. Human Sir2 and the 'silencing' of p53 activity. Trends Cell Biol. 2002; 12(9):404-406.
32. Lambert PF, Kashanchi F, Radonovich MF, Shiekhattar R, Brady JN. Phosphorylation of p53 serine 15 increases interaction with CBP. J Biol Chem. 1998; 273(49):33048-33053.
33. Meek DW, Anderson CW. Posttranslational modification of p53: cooperative integrators of function. Cold Spring Harb Perspect Biol. 2009; 1(6):a000950.
34. Shieh SY, Ikeda M, Taya Y, Prives C. DNA damageinduced phosphorylation of p53 alleviates inhibition by MDM2. Cell. 1997; 91(3):325-334.
35. Saito S, Goodarzi AA, Higashimoto Y, Noda Y, Lees-Miller SP, Appella E, Anderson CW. ATM mediates phosphorylation at multiple p53 sites, including Ser(46), in response to ionizing radiation. J Biol Chem. 2002; 277(15):12491-12494.
36. Sakaguchi K, Herrera JE, Saito S, Miki T, Bustin M, Vassilev A, Anderson CW, Appella E. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev. 1998; 12(18):2831-2841.
37. Li Z, Jiao X, Wang C, Shirley LA, Elsaleh H, Dahl O, Wang M, Soutoglou E, Knudsen ES, Pestell RG. Alternative cyclin d1 splice forms differentially regulate the DNA damage response. Cancer Res.2010; 70(21):8802-8811.
38. Ard PG, Chatterjee C, Kunjibettu S, Adside LR, Gralinski LE, McMahon SB. Transcriptional regulation of the mdm2 oncogene by p53 requires TRRAP acetyltransferase complexes. Mol Cell Biol. 2002; 22(16):5650-5661.
39. Zhang Z, Chen G, Cheng Y, Martinka M, Li G. Prognostic significance of RUNX3 expression in human melanoma. Cancer. 2011; 117(12):2719-2727.
40. Zhong Z, Yeow WS, Zou C, Wassell R, Wang C, Pestell RG, Quong JN, Quong AA. Cyclin D1/cyclin-dependent kinase 4 interacts with filamin A and affects the migration and invasion potential of breast cancer cells. Cancer Res. 2010; 70(5):2105-2114.
41. Liu M, Ju X, Willmarth NE, Casimiro MC, Ojeifo J, Sakamaki T, Katiyar S, Jiao X, Popov VM, Yu Z, Wu K, Joyce D, Wang C, Pestell RG. Nuclear factor-kappaB enhances ErbB2-induced mammary tumorigenesis and neoangiogenesis in vivo. Am J Pathol. 2009; 174(5):1910-1920